Dimitry Ofengeim

Dimitry Ofengeim

Company: Sanofi

Job title: Head of Precision Neurology & Neuroinflammation Cluster

Seminars:

Investigating Pathways for Intervention: Targeting RIPK1 in ALS 1:30 pm

Assessing RIPK1 kinase activity modulates inflammatory signaling in microglia and astrocytes RIPK1 is elevated in ALS patient spinal cords and RIPK1 kinase inhibition delays ALS disease progression in the SOD1G93A mouse model Reviewing the Himalaya trial using a RIPK1 inhibitor to treat ALS patientsRead more

day: Day Two

Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies 11:00 am

Dissecting causative genes and cellular processes involved in ALS pathogenesis to shape future directions of therapeutic development C9orf72, SOD1 & TDP-43: mapping promising targets Can we move the needle in genetically defined patient populations and translate learnings to patients with sporadic ALS?Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.